B+
Bull case
25%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
PACS
PACS GroupBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$49.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-21
Recent news sentiment (30D)
+70.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+74.3
Score
AI commentary
Company and SEC earnings evidence is moderately positive, but the deterministic score remains neutral with low modeled forward returns. Social coverage, options positioning, short interest, employee sentiment, analyst revisions, and post-print market reaction are unavailable; missing data is not treated as positive evidence. Recent insider sales add a monitoring flag. [#SEC-8K-2026-08-04] [#SEC-FORM4-2026-08-19]
RankAlpha Sentiment Codex - 2026-08-21
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 earnings execution and 2026 outlookMedium impact
Q2 revenue was $1.43 billion, adjusted EBITDA $166.8 million, diluted EPS $0.47, and overall occupancy 90.4%. Stored earnings-call context also reports 2026 revenue guidance of $5.75-$5.85 billion and adjusted EBITDA guidance of $640-$660 million. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-12]
2026-12-31catalystExecution, regulatory, and insider-selling overhangHigh impact
Integration of acquired facilities, reimbursement and quality-payment uncertainty, and recent open-market sales by senior insiders could limit multiple expansion or pressure sentiment. Insider activity supports only an ownership signal, not an operating conclusion. [#SEC-FORM4-2026-08-19]
2026-12-31catalystPortfolio maturation and acquisition-led growthHigh impact
Existing-portfolio performance, improving occupancy and skilled mix, high CMS quality ratings, and the planned addition of 34 Eduro facilities support continued operating improvement if integration remains disciplined. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-21 • Updated nightlySource: Internal modelMethodology